Valproic Acid and Levetiracetam Together: What FDA Data Reveals About This Seizure Drug Combination

A 54-year-old woman with a 20-year history of treatment-resistant epilepsy arrived at her neurology clinic frustrated. Her current regimen of levetiracetam wasn't controlling her seizures well enough. Her neurologist, considering her medical history and previous medication failures, proposed adding valproic acid to boost seizure control. Before filling the prescription, the patient's pharmacist pulled up her full medication record. "I want to make sure these two work safely together," the pharmacist said. "Let me verify the latest information." This scenario plays out regularly in clinics and pharmacies across the country—and it underscores an important truth: when two antiepileptic drugs are combined, safety verification matters.

Overview: Two Common Seizure Medications, One Important Question

Valproic acid (also called divalproex or valproate) and levetiracetam (Keppra) are among the most widely prescribed antiepileptic drugs in the United States. Both are used to treat epilepsy, prevent seizures after brain injury, and manage certain types of migraine headaches. Because they work through different mechanisms—valproic acid affects multiple neurotransmitter systems and GABA metabolism, while levetiracetam binds to a specific synaptic protein—physicians sometimes prescribe them together to achieve better seizure control. However, combining any two medications requires careful assessment of whether they interact adversely.

The key question patients and providers ask is simple but critical: Is it safe to take valproic acid and levetiracetam at the same time? The answer, based on current FDA labeling and clinical evidence, is nuanced.

What the FDA Says: Labeling and Evidence

When we examine the FDA drug labels for both medications, we find important information. The U.S. FDA label for valproic acid lists numerous drug interactions, drug-disease interactions, and warnings about hepatotoxicity, pancreatitis, and birth defect risk. The FDA label for levetiracetam similarly documents potential neuropsychiatric side effects and warns about serious skin reactions.

However, there is no documented contraindication or formally ranked interaction between valproic acid and levetiracetam in the standard FDA labeling databases. This does not mean they are risk-free together—it means that the FDA has not flagged a major pharmacokinetic or pharmacodynamic interaction that would prevent their concurrent use.

That said, clinical experience and post-market surveillance (captured in the FDA Adverse Event Reporting System, or FAERS) do document cases where patients taking both drugs together experienced adverse events. These reports are not formal "interactions" in the traditional sense, but rather represent the cumulative risk profile when two CNS-active drugs are combined.

Severity and Risk Level: What We Know and Don't Know

The lack of a documented interaction ranking does not mean zero risk. Instead, it reflects a more subtle concern: additive CNS depression and potential for increased adverse effects.

Both valproic acid and levetiracetam are known to cause:

• Dizziness and drowsiness — especially when doses are first started or increased
• Cognitive effects — difficulty concentrating, memory problems, or confusion
• Behavioral changes — mood changes, irritability, or depression (levetiracetam is particularly associated with neuropsychiatric side effects)
• Tremor and ataxia — loss of coordination or unsteadiness

When taken together, these effects may compound. A patient might experience more pronounced drowsiness, cognitive slowing, or mood disturbance than if either drug were used alone. Additionally, valproic acid can increase the serum levels of certain metabolites of levetiracetam, though the clinical significance of this is not fully established.

The FDA classification for this pair is best understood as moderate vigilance required—not contraindicated, but requiring close monitoring and dose optimization.

Who Is Most at Risk

Certain patient populations face heightened risk if valproic acid and levetiracetam are combined without careful oversight:

• Older adults — age 65 and over often experience exaggerated CNS effects from antiepileptic drugs
• Patients with liver disease — both drugs are metabolized hepatically; impaired liver function increases exposure and risk
• Patients with renal impairment — levetiracetam is renally cleared; reduced kidney function raises drug levels
• Those with baseline cognitive impairment or psychiatric illness — levetiracetam's neuropsychiatric side effects may be more pronounced
• Pregnant women — valproic acid carries high teratogenic risk; combination therapy must be urgently reassessed if pregnancy occurs
• Patients taking multiple other CNS depressants — benzodiazepines, opioids, or other anticonvulsants amplify CNS depression risk

What to Do If You Take Both Medications

Do not stop either medication without consulting your prescribing neurologist or physician. Abruptly discontinuing antiepileptic drugs can precipitate dangerous seizures. Instead, follow these steps:

• Verify with your pharmacist. Give your pharmacist a complete list of all medications, supplements, and herbal products. Ask them specifically to review the valproic acid and levetiracetam combination for safety.
• Report your baseline symptoms. Before starting or adjusting doses, tell your doctor about any dizziness, drowsiness, mood changes, or cognitive issues you already experience.
• Start low and go slow. If your doctor is initiating or increasing either medication, request the lowest effective dose, increased gradually as tolerated.
• Monitor your response closely. Keep a brief log of how you feel—your energy, mood, concentration, and seizure frequency—for at least the first 2-4 weeks after any dose change.
• Avoid driving or operating machinery until you are confident the combination is not impairing your alertness or coordination.

When to Call Your Doctor

Contact your prescribing physician immediately if you experience:

• Severe drowsiness, difficulty waking, or loss of consciousness
• New or worsening mood changes, depression, thoughts of self-harm, or suicidal thoughts (especially important with levetiracetam)
• Significant cognitive changes, such as difficulty speaking, severe confusion, or memory loss
• Loss of seizure control or new types of seizures
• Severe tremor, loss of coordination, or difficulty walking
• Signs of liver injury: yellowing of skin or eyes, dark urine, pale stools, abdominal pain, nausea
• Signs of pancreatitis: severe upper abdominal pain, persistent vomiting (more likely with valproic acid)
• Any rash, blistering, or signs of serious skin reaction

Bottom Line

Valproic acid and levetiracetam are not formally contraindicated according to FDA drug labeling, and many patients take them together successfully under medical supervision. However, this combination does carry the potential for additive CNS depression and other compound effects that require careful monitoring, especially in vulnerable populations such as older adults, those with liver or kidney disease, and patients with baseline psychiatric or cognitive conditions.

The safety of this combination depends entirely on thoughtful prescribing, appropriate dosing, patient education, and vigilant follow-up. Your neurologist and pharmacist are your best resources for assessing whether this specific combination is right for you and for catching problems early if they arise.

Don't rely on memory or guesswork when it comes to your medication safety. Your complete drug profile matters. Use checkdruginteractions.com—the most comprehensive drug interaction checker on the internet, powered by over 250,000 FDA-sourced drug records—to verify your entire medication list instantly. No account needed. Check up to 20 drugs at once and get clarity on every interaction before leaving the pharmacy. Your safety is worth those few minutes.